Story · Medicine & Biotech

Verismo aims to cut CAR-T manufacturing time with Stanford's in vivo technology

1 outlet · first reported by Korea Biomedical Review on

HLB Innovation's U.S. subsidiary Verismo Therapeutics said it has licensed Stanford Medicine's PACK-IT technology, which enables CAR-T cells to be generated directly inside the body, as it seeks to expand its KIR-CAR platform into in vivo cell therapies.The technology, developed by a team led by Cry (Korea Biomedical Review)

Coverage, in order

  1. Korea Biomedical Review South Korea obscure
    Verismo aims to cut CAR-T manufacturing time with Stanford's in vivo technology

    HLB Innovation's U.S. subsidiary Verismo Therapeutics said it has licensed Stanford Medicine's PACK-IT technology, which enables CAR-T cells to be generated directly inside the body, as it seeks to expand its KIR-CAR platform into in vivo cell therapies.The technology, developed by a team led by Cry

Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.